Pursuits of Business - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pursuits of Business


Pharmaceutical Technology


Maribel Rios
The Parenteral Drug Association recently held its first global conference on emerging manufacturing technologies. Among the presentations were those discussing the latest in disposable technologies, aseptic filling and closing, and barrier systems. Clearly, technology vendors have stepped up efforts to streamline processes and better handle complex drug products.

Whether manufacturers are ready to implement these technologies, however, wasn't so obvious. During a luncheon, my tablemates debated over whether drug makers will ever be able to provide personalized medicine. In the end, they generally agreed this was a long way from fruition. But the conversation prompted a PDA official to pose an even tougher question: Faced with two compounds, one that is simple, easy to manufacture, but must be administered monthly, and another that is much more complex but can be taken only once a year, which would you pursue to market?

What was so surprising was that, unlike the personalized-medicines issue, no one offered an immediate and definitive opinion. After a seemingly long silence, the pros and cons were weighed: How long would the simpler formulation sustain a reasonable market share before a competitive product was marketed that required less frequent dosing? Would the inconvenience of more frequent dosing have a higher risk for patient noncompliance? The complex formulation would cost more and carry a higher risk of error during development, but it offered a preferred dosage regimen and patient compliance would (theoretically) be greater.

The general consensus was that, all points considered, manufacturers could not afford not to pursue the once-per-year dose. Patient-focused healthcare is here and now, ready or not. Sooner rather than later, technologies will have to be updated, not only, as one speaker stated, because "the aggressive use of technology makes good business sense," but also because it will soon be common sense.

Maribel Rios is a senior editor of Pharmaceutical Technology,
.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here